Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ / shares in Units, $ in Thousands, € in Millions																										1 Months Ended							3 Months Ended					9 Months Ended		12 Months Ended
	May 19, 2021 USD ($)	May 19, 2021 USD ($)	May 19, 2021 USD ($) leaseAgreement	May 19, 2021 USD ($) performanceObligation	May 19, 2021 USD ($) program	Apr. 24, 2021 USD ($)	Apr. 01, 2021 USD ($) $ / shares shares	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($) swapOption program performanceObligation license researchProgram	May 02, 2017 USD ($)	May 02, 2017 USD ($)	May 02, 2017 USD ($) leaseAgreement	May 02, 2017 USD ($) performanceObligation	May 02, 2017 USD ($) researchProgram	May 02, 2017 USD ($) license	May 02, 2017 USD ($) protein	Jan. 04, 2017 collaborationProduct product	Jan. 04, 2017 USD ($) collaborationProduct product	Jan. 04, 2017 performanceObligation product collaborationProduct	Jan. 04, 2017 collaborationProduct program product	Jan. 04, 2017 license product collaborationProduct	Jan. 04, 2017 bispecificTherapeuticProgram product collaborationProduct	Jan. 04, 2017 EUR (€) collaborationProduct product	Jan. 04, 2017 preclinicalMilestone collaborationProduct product	Jan. 04, 2017 collaborationProduct extensionOption product	Mar. 31, 2021 USD ($)	Feb. 28, 2021	Feb. 29, 2020 program collaborationProduct	Feb. 28, 2019 USD ($)	Feb. 28, 2019 EUR (€)	Dec. 31, 2018 USD ($) preclinicalMilestone	Dec. 31, 2018 EUR (€) preclinicalMilestone	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)	Jan. 01, 2019 USD ($)	May 02, 2017 performanceObligation	May 02, 2017 collaborationProduct
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																																	$ 1,900					$ 3,500
Deferred revenues, current portion																																	26,449					26,449		$ 12,627
Deferred revenue, net of current portion																																	46,190					46,190		35,900
Number of technology licenses \| leaseAgreement												5
Total revenue																																	4,057		$ 2,939			22,975	$ 27,446
Number of separate performance obligations \| performanceObligation																			1
Amortization of capitalized contract costs																																							100
Additions to deferred revenue																																	1,500					31,600
License fees
Disaggregation of Revenue [Line Items]
Deferred revenues, current portion																																	5,800					5,800
Genentech
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, variable consideration amount	$ 1,400,000	$ 1,400,000	$ 1,400,000	$ 1,400,000	$ 1,400,000
Fee on additional program		10,000
Termination notice period within material breach	90 days
Before first commercial sale	90 days
After first commercial sale	180 days
Number of research programs			4		2
Remaining performance obligation																																	18,100					18,100
Total revenue																																	863		0			863	0
Genentech \| License fees
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 20,000	$ 20,000	$ 20,000	$ 20,000	$ 20,000
Deferred revenues, current portion																																	5,100					5,100
Deferred revenue, net of current portion																																	13,000					13,000
Genentech \| Research and Development Services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term	3 years
Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation									3
Remaining performance obligation																																	22,500					22,500
Resale of stock period								60 days
Deferred revenues, current portion																																	8,700					8,700
Deferred revenue, net of current portion																																	10,600					10,600
Total revenue																																	(280)		366			424	9,326
AstraZeneca
Disaggregation of Revenue [Line Items]
Deferred revenue																																	700					700
Remaining performance obligation																																	19,800					19,800
Resale of stock period							60 days
Deferred revenues, current portion																																	800					800
Deferred revenue, net of current portion																																	17,600					17,600
Research collaboration agreement term										5 years
Total revenue																										$ 13,000							1,607	$ 13,000	2,182			18,309	7,227
Amortization of capitalized contract costs																																	0		0			0	0
Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation																			10
Revenue recognized from contract with customer																																					$ 7,100
Remaining performance obligation																																	10,900					10,900
Deferred revenues, current portion																																	6,000					6,000
Deferred revenue, net of current portion																																	5,000					5,000
Number of novel proteins \| bispecificTherapeuticProgram																						1
Number of programs																				3		3
Total revenue																																	1,867		391			3,379	$ 10,893
Capitalized contract cost, net																																	100					100
Number of separate performance obligations \| performanceObligation																			2
Number of combined performance obligations \| performanceObligation																			2
Research term, extension period																											12 months	12 months
Number of preclinical stage programs \| program																												2
Preclinical stage performance obligation period																												60 days
Amortization of capitalized contract costs																																	0		$ 0			0
Les Laboratoires Servier and Institut de Recherches Internationales Servier \| Research and Development Services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term																	3 years
Number of preclinical milestones \| preclinicalMilestone																								2							1	1
Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Remaining performance obligation						$ 6,000
Contract with customer asset, after allowance for credit loss						4,000
Exclusive Product License Agreement \| Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Deferred revenue						10,000
Revenue, remaining performance obligation, variable consideration amount						352,500
Contribution on manufacturing (up to)						$ 4,000
Period after effective date agreements may be terminated						9 months
Contract termination advance notice period						60 days
Agreement termination advance notice period if marketing approval obtained						120 days
Agreement termination notice period upon material breach by the Company						180 days
Contract termination due to material breach, additional notice period if the breach is not susceptible						180 days
Remaining performance obligation																																	5,800					5,800
Collaborative arrangement, agreement obligation cost						$ 4,000
Agreement termination notice period due to non-payment of undisputed amounts						60 days
License and Collaboration Agreement \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation				5
License and Collaboration Agreement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs \| researchProgram									3
Period after effective date agreements may be terminated									12 months
Contract termination advance notice period									90 days
Agreement termination advance notice period if marketing approval obtained									180 days
Agreement termination notice period upon material breach by the Company									90 days
Contract termination due to material breach, additional notice period if the breach is not susceptible									90 days
Number of licenses \| license									3
Number of swap options \| swapOption									2
Number of performance obligations \| performanceObligation									6
License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated										12 months
Contract termination advance notice period										90 days
Agreement termination advance notice period if marketing approval obtained										180 days
Agreement termination notice period upon material breach by the Company										180 days
Contract termination due to material breach, additional notice period if the breach is not susceptible										180 days
Number of performance obligations \| performanceObligation													16
Number of novel proteins \| protein																4
Agreement termination notice period upon breach of payment obligations by the Company										30 days
Period of license performance obligation										12 months
License and Collaboration Agreement \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of licenses \| license																					5
Number of performance obligations \| performanceObligation																			4
Number of collaboration products \| collaborationProduct																	2	2	2	2	2	2	2	2	2
Number of programs \| bispecificTherapeuticProgram																						5
Strategic Partnerships and Other License Agreements \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated																	12 months
Contract termination advance notice period																	180 days
Revenue recognized from contract with customer																													$ 1,700	€ 1.5	$ 600	€ 0.5
Number of collaboration products \| product																	4	4	4	4	4	4	4	4	4
Other arrangement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs \| researchProgram									2
Platform technology license \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation				2
Number of target programs \| program					2
Platform technology license \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation									3
Number of target programs \| program									3
Antibody target swap \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation				2
Antibody target swap \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation									2
Governance committee participation \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation				1
Governance committee participation \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performanceObligation									1
Upfront Payment \| Seagen
Disaggregation of Revenue [Line Items]
Deferred revenue									$ 1,200,000
Research and development services									4,900
Upfront Payment \| Seagen \| License fees
Disaggregation of Revenue [Line Items]
Revenue									$ 30,000
Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											$ 45,000
Upfront Payment \| Les Laboratoires Servier and Institut de Recherches Internationales Servier \| License fees
Disaggregation of Revenue [Line Items]
Revenue																		$ 32,000					€ 30.0
Upfront Payment \| Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Remaining performance obligation						$ 10,000
Additional other research services \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											4,700
Servier Developed Collaboration Product \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products \| collaborationProduct																												1
Co-Development Collaboration Product \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products \| collaborationProduct																												1
Estimated Development and Manufacturing Services \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											14,200
Milestone Payments \| Upfront Payment \| Seagen
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																																								$ 4,200
Allocable arrangement consideration																																				$ 5,000
Milestone Payments \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											12,500
Estimated Phase 2a Services \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											4,700
Agreement extension options (in extension options) \| Les Laboratoires Servier and Institut de Recherches Internationales Servier \| Research and Development Services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term																	1 year
Number of agreement extension options \| extensionOption																									2
Minimum \| License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products \| collaborationProduct																																											2
Minimum \| Strategic Partnerships and Other License Agreements \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company																	90 days
Maximum \| License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products																	4	4	4	4	4	4	4	4	4																	4	4
Number of programs \| researchProgram														2
Number of research licenses												4			4						4
Maximum \| Strategic Partnerships and Other License Agreements \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company																	120 days
Accounting Standards Update 2014-09 \| AstraZeneca
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net										$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600																	$ 700					$ 700
Capitalized contract cost in accordance with ASC 340																																									$ 1,100
Accounting Standards Update 2014-09 \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net																																									$ 500
Private placement \| Seagen
Disaggregation of Revenue [Line Items]
Deferred revenue								$ 3,300
Shares of stock sold (in shares) \| shares								3,706,174
Shares of stock sold, net consideration								$ 13,000
Shares of stock sold, price (USD per share) \| $ / shares								$ 3.51
Fair value of stock (in dollars per share) \| $ / shares								$ 2.61
Private placement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Shares of stock sold (in shares) \| shares							3,584,230
Shares of stock sold, net consideration							$ 10,000
Shares of stock sold, price (USD per share) \| $ / shares							$ 2.79
Fair value of stock (in dollars per share) \| $ / shares							$ 2.60